niacin and mk-0524

niacin has been researched along with mk-0524 in 76 studies

Research

Studies (76)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	15 (19.74)	29.6817
2010's	61 (80.26)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Crumley, TM; De Lepeleire, I; Gottesdiener, K; Lai, E; Liu, F; Michiels, N; O'Neill, G; Vets, E; Wagner, JA; Wenning, LA	1
Ballantyne, CM; Bays, HE; Davidson, M; Kher, U; Lai, E; Meehan, AG; Mitchel, YB; Norquist, JM; Paolini, JF; Reyes, R; Watson, DJ	1
Felts, AS	1
Ballantyne, CM; Bays, HE; Davidson, M; Kuznetsova, O; Lai, E; Maccubbin, D; Mitchel, YB; Norquist, JM; Paolini, JF; Pasternak, R; Sisk, CM; Waters, MG	1
Ansell, BJ	1
Bays, HE; Betteridge, A; Elinoff, V; Elis, A; Kuznetsova, O; Maccubbin, D; Mitchel, Y; Olsson, AG; Paolini, JF; Pasternak, RC; Reyes, R; Sirah, W; Sisk, CM; Yu, Q	1
Bays, HE; Kuznetsova, O; Maccubbin, D; Meehan, AG; Mitchel, YB; Paolini, JF	1
Atiee, GJ; Dishy, V; Ebel, DL; Lai, E; Liu, F; Paolini, JF; Reilley, S; Royalty, J; Wagner, JA	1
Davidson, M; Gavish, D; Koren, MJ; Maccubbin, D; Macdonell, G; Mallick, M; Mitchel, Y; Paolini, JF; Pasternak, RC; Sisk, CM	1
Chen, E; Hu, DY; Kim, HS; Kush, D; Maccubbin, D; McCrary Sisk, C; Paolini, JF; Sirah, W; Ye, P	1
Perry, CM	1
Ballantyne, C; Bays, HE	1
Chao, A; Cote, J; Dishy, V; Gutierrez, M; Lai, E; Larson, P; Laterza, O; Lauring, B; Luo, WL; Patterson, J; Wagner, JA	1
Arora, R; Sood, A	1
Parhofer, KG	1
Cheung, BM; Tse, HF; Yiu, KH	1
Chodakewitz, JA; Dallob, A; Jumes, P; Kraft, WK; Lai, E; Liu, F; McCrary Sisk, C; Radziszewski, W; Royalty, J; Schwartz, JI; Wagner, JA	1
Bostom, AG; Hanlon, WA; Kuznetsova, O; Maccubbin, D; Tipping, D	1
Johnson-Levonas, AO; Lai, E; Lasseter, KC; Liu, F; Luk, JA; Lunde, NM; Marbury, TC; Nirula, A; Wagner, JA; Wang, YH	1
Olsson, AG	1
Ceska, R; Giezek, H; Gil-Extremera, B; Maccubbin, D; Mao, A; McCrary Sisk, C; Paolini, JF; Shah, S; Vandormael, K	1
Karas, RH; Kuvin, JT; Sanyal, S	1
Elisaf, MS; Florentin, M; Kei, A; Liberopoulos, EN; Mikhailidis, DP	1
Bays, H; Dong, Q; Maccubbin, D; McCrary Sisk, C; Shah, A	1
Davies, GM; Krobot, KJ; Michailov, GV	1
Bostom, AG; Ganjoo, P; Ix, JH; Tershakovec, AM; Tipping, D	1
Chyu, KY; Peter, A; Shah, PK	1
Markel, A	1
Sharpe, P	1
Ammori, BJ; Issa, B; Kwok, S; Soran, H; Yadav, R	1
Blomqvist, P; Chen, E; Chen, F; Davidson, M; Maccubbin, D; McKenney, JM; Sirah, W; Sisk, CM; Yan, L	1
Bays, H; Giezek, H; McKenney, JM; O'Neill, EA; Tershakovec, AM	1
Bays, HE; Dong, Q; Lin, J; Maccubbin, D; Shah, A; Sisk, CM	1
Hanefeld, M; Stahn, A	1
Aw, DC; Ho, SA	1
Ammori, BJ; France, M; Hama, S; Kwok, S; Soran, H; Yadav, R; Younis, N	1
Anderson, JW; Bays, HE; Chen, F; Kher, U; Maccubbin, DL; McCrary Sisk, C; Mitchel, YB; Olsson, AG; Sirah, W	1
Frank, S; Heinemann, A; Konya, V; Lazarevic, M; Marsche, G; Pasterk, LM; Peskar, BA; Philipose, S; Schuligoi, R	1
Buffleben, C; Dänschel, W; Hildemann, SK; Pittrow, D; Steinhagen-Thiessen, E	1
Buffleben, C; Dänschel, W; Hildemann, SK; Pittrow, D; Smolka, W; Steinhagen-Thiessen, E	1
Landmesser, U	1
Wierzbicki, AS	1
Elisaf, M; Kei, A; Liberopoulos, E; Rizzo, M; Tellis, K; Tselepis, A	1
Gotto, AM; Rosenson, RS	1
Egom, EE; Mamas, MA; Soran, H	1
Bregar, U; Cevc, M; Jug, B; Keber, I; Sebestjen, M	1
Cabré, A; Masana, L; Plana, N	1
Chang, M; Hu, M; Tomlinson, B; Yang, YL	1
Tofield, A	1
Bea, AM; Calmarza, P; Cenarro, A; Civeira, F; Ferrando, J; Jarauta, E; Mateo-Gallego, R; Puzo, J	1
Afolabi, P; Atkin, SL; Aye, MM; Coady, AM; Kilpatrick, ES; Rigby, AS; Sandeman, DD; Wootton, SA	1
Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A	1
Mayor, S	1
Azevedo Moura, F; Coelho, OR; Colontoni, BA; de Faria, EC; Nasser Figueiredo, V; Quinaglia, T; Roberto Matos-Souza, J; Sposito, AC; Vendrame, F	1
Bostom, A; Ix, JH; Rao, M; Steffes, M	1
Chen, E; Farnier, M; Johnson-Levonas, AO; McCrary Sisk, C; Mitchel, YB	1
Armitage, J; Aung, T; Collins, R; Craig, M; Haynes, R; Hopewell, JC; Jiang, L; Landray, MJ; Parish, S; Tomson, J; Wallendszus, K	1
Lloyd-Jones, DM	1
McCarthy, M	1
Amigó, N; Ascaso, JF; Blanco-Vaca, F; Cabré, A; Correig, X; Girona, J; Heras, M; Julve, J; Martínez-Hervás, S; Masana, L; Palomer, X; Plana, N; Quesada, H; Real, JT; Vázquez-Carrera, M	1
Bays, HE; Brinton, EA; Chen, E; Gibson, KL; Johnson-Levonas, AO; Maccubbin, D; MacLean, AA; Mitchel, YB; O'Neill, EA; Ruck, RA; Triscari, J	1
Brophy, JM; Labos, C; Thanassoulis, G	1
Hu, M; Masuda, D; Tomlinson, B; Yamashita, S; Yang, YL	1
Chan, P; Hu, M; Tomlinson, B; Yang, YL	1
Abbate, R; Bandinelli, B; Cioni, G; Costanzo, M; D'Alessandri, G; Fatini, C; Liotta, AA; Mannini, L; Marcucci, R	1
Ammori, BA; Donn, R; Durrington, P; Eatough, R; France, M; Hama, S; Issa, B; Kwok, S; Liu, Y; Malik, R; Pemberton, P; Schofield, J; Siahmansur, TJ; Soran, H; Stevens, A; Yadav, R; Younis, N	1
Chapman, J; Couvert, P; El Khoury, P; Frisdal, E; Gall, J; Guerin, M; Huby, T; Lacorte, JM; Le Goff, W; Lesnik, P; Parhofer, KG; Waldmann, E	1
Amigó, N; Blanco Vaca, F; Correig, X; Escolà-Gil, JC; Heras, M; Mallol, R; Martínez-Hervás, S; Masana, L; Plana, N; Yanes, Ó	1
Brinton, EA; Brudi, P; Chen, E; Johnson-Levonas, AO; Maccubbin, D; MacLean, AA; Mitchel, YB; Ruck, RA; Sisk, CM; Triscari, J	1
Armitage, J; Collins, R; Gray, A; Haynes, R; Hopewell, JC; Kent, S; Landray, MJ; Mihaylova, B; Parish, S	1
Armitage, J; Baigent, C; Collins, R; Haynes, R; Hill, MR; Hopewell, JC; Landray, M; Marcovina, S; Offer, A; Parish, S; Pedersen, TR; Valdes-Marquez, E	1
Armitage, J; Chen, F; Haynes, R; Hopewell, JC; Landray, MJ; Li, J; Parish, S; Valdes-Marquez, E	1
Armitage, J; Bowman, L; Chen, F; Dayanandan, R; Haynes, R; Landray, MJ; Lay, MJ; Parish, S; Wincott, E	1

Reviews

16 review(s) available for niacin and mk-0524

Article	Year
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiology clinics, 2008, Volume: 26, Issue:4 Topics: Animals; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Flushing; Humans; Hypolipidemic Agents; Indoles; Lipids; Niacin; Receptors, Immunologic; Receptors, Prostaglandin	2008
A review of trials evaluating nonstatin lipid-lowering therapies. Current atherosclerosis reports, 2009, Volume: 11, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Niacin	2009
Extended-release niacin (nicotinic acid)/laropiprant. Drugs, 2009, Aug-20, Volume: 69, Issue:12 Topics: Chemistry, Pharmaceutical; Cholesterol, LDL; Delayed-Action Preparations; Drug Combinations; Drug Interactions; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic; Receptors, Prostaglandin	2009
What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Current opinion in lipidology, 2009, Volume: 20, Issue:6 Topics: Coronary Disease; Delayed-Action Preparations; Drug Combinations; Flushing; Humans; Hypolipidemic Agents; Indoles; Lipids; Niacin; Treatment Outcome	2009
Mechanisms of flushing due to niacin and abolition of these effects. Journal of clinical hypertension (Greenwich, Conn.), 2009, Volume: 11, Issue:11 Topics: Aspirin; Dose-Response Relationship, Drug; Dyslipidemias; Humans; Hypolipidemic Agents; Indoles; Niacin; Pruritus	2009
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vascular health and risk management, 2009, Volume: 5 Topics: Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Flushing; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Lipids; Lipoprotein(a); Niacin; Receptors, Immunologic; Receptors, Prostaglandin; Treatment Outcome; Triglycerides	2009
A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin. Expert opinion on investigational drugs, 2010, Volume: 19, Issue:3 Topics: Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Niacin; Simvastatin	2010
Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:10 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Flushing; Humans; Indoles; Lipid Metabolism; Niacin	2010
Niacin and laropiprant. Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46, Issue:6 Topics: Cholesterol, HDL; Drug Tolerance; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, HDL; Niacin; Receptors, Immunologic; Receptors, Prostaglandin; Safety; Weight Loss	2010
Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Current vascular pharmacology, 2011, Jul-01, Volume: 9, Issue:4 Topics: Animals; Cholesterol, HDL; Drug Therapy, Combination; Flushing; Glucose; Homocysteine; Humans; Hypolipidemic Agents; Indoles; Niacin; Receptors, Immunologic; Receptors, Prostaglandin; Uric Acid	2011
Progress in HDL-based therapies for atherosclerosis. Current atherosclerosis reports, 2011, Volume: 13, Issue:5 Topics: Animals; Apolipoproteins; Atherosclerosis; Dyslipidemias; Endothelium, Vascular; Fibric Acids; Fibrinolysis; Gene Transfer Techniques; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, HDL; Lipoproteins, LDL; Niacin; Oxidation-Reduction; Risk Factors; Thrombosis	2011
The resurgence of niacin: from nicotinic acid to niaspan/laropiprant. The Israel Medical Association journal : IMAJ, 2011, Volume: 13, Issue:6 Topics: Cholesterol; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Nicotinic Acids; Treatment Outcome; Vitamin B Complex	2011
Safety and tolerability of extended-release niacin with laropiprant. Expert opinion on drug safety, 2012, Volume: 11, Issue:1 Topics: Animals; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Flushing; Humans; Hypolipidemic Agents; Indoles; Niacin	2012
[Multimodal therapy of dyslipidemia]. Clinical research in cardiology supplements, 2011, Volume: 6 Topics: Animals; Biomarkers; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Omega-3; Fibric Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipids; Niacin; Practice Guidelines as Topic; Treatment Outcome	2011
Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:9 Topics: Animals; Cardiovascular Diseases; Delayed-Action Preparations; Dyslipidemias; Evidence-Based Medicine; Flushing; Humans; Hypolipidemic Agents; Indoles; Lipids; Niacin; Practice Guidelines as Topic; Treatment Outcome	2012
HDL quality or cholesterol cargo: what really matters--spotlight on sphingosine-1-phosphate-rich HDL. Current opinion in lipidology, 2013, Volume: 24, Issue:4 Topics: Animals; Atherosclerosis; Cardiotonic Agents; Cholesterol, HDL; Coronary Artery Disease; Drug Therapy, Combination; Humans; Indoles; Lysophospholipids; Niacin; Randomized Controlled Trials as Topic; Sphingosine; Treatment Outcome	2013

Trials

37 trial(s) available for niacin and mk-0524

Article	Year
Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clinical pharmacology and therapeutics, 2007, Volume: 81, Issue:6 Topics: Adolescent; Adult; Aspirin; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Niacin; Receptors, Immunologic; Receptors, Prostaglandin; Regional Blood Flow; Skin; Vasodilation; Vasodilator Agents	2007
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. The American journal of cardiology, 2008, Mar-01, Volume: 101, Issue:5 Topics: Adolescent; Adult; Aged; Creatine Kinase; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Flushing; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Receptors, Immunologic; Receptors, Prostaglandin	2008
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International journal of clinical practice, 2008, Volume: 62, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Treatment Outcome; Young Adult	2008
Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. Journal of clinical pharmacology, 2009, Volume: 49, Issue:4 Topics: Administration, Oral; Adult; Aged; Aspirin; Cross-Over Studies; Cyclooxygenase Inhibitors; Delayed-Action Preparations; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Flushing; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Placebos; Receptors, Immunologic; Receptors, Prostaglandin	2009
Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. The American journal of cardiology, 2009, Jul-01, Volume: 104, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Confidence Intervals; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Flushing; Health Status Indicators; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Myocardial Ischemia; Niacin; Receptors, Immunologic; Receptors, Prostaglandin; Risk Factors; Surveys and Questionnaires; Young Adult	2009
Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Cardiology, 2009, Volume: 114, Issue:3 Topics: Adult; Aged; Asian People; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Flushing; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin	2009
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. Journal of clinical pharmacology, 2009, Volume: 49, Issue:12 Topics: Adolescent; Adult; Aged; Biomarkers; Blood Platelets; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus; Double-Blind Method; Epoprostenol; Female; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Niacin; Platelet Activation; Prostaglandin D2; Receptors, Immunologic; Receptors, Prostaglandin; Thromboxane B2; Young Adult	2009
Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets, 2010, Volume: 21, Issue:3 Topics: Adolescent; Adult; Aged; Bleeding Time; Collagen; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Niacin; Placebos; Platelet Aggregation; Reference Values; Sensitivity and Specificity; Young Adult	2010
Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:4 Topics: Aged; Biomarkers; Calcium; Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Glomerular Filtration Rate; Humans; Hyperphosphatemia; Hypolipidemic Agents; Hypophosphatemia; Indoles; Kidney Diseases; Male; Middle Aged; Niacin; Phosphorus; Receptors, Immunologic; Receptors, Prostaglandin; Severity of Illness Index; Time Factors	2010
Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment. Journal of clinical pharmacology, 2011, Volume: 51, Issue:3 Topics: Female; Flushing; Half-Life; Hepatic Insufficiency; Humans; Indoles; Male; Middle Aged; Niacin; Protein Isoforms; Receptors, Immunologic; Receptors, Prostaglandin; Severity of Illness Index	2011
Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International journal of clinical practice, 2010, Volume: 64, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Prostaglandin D2; Treatment Outcome; Young Adult	2010
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Dyslipidemias; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Risk Factors; Treatment Outcome; Triglycerides	2011
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. International journal of cardiology, 2013, Jul-15, Volume: 167, Issue:1 Topics: Adult; Aged; Atorvastatin; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome	2013
Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic syndrome and related disorders, 2012, Volume: 10, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Chylomicrons; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypolipidemic Agents; Indoles; Lipids; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Placebos; Triglycerides	2012
Effectiveness and safety of laropiprant on niacin-induced flushing. The American journal of cardiology, 2012, Sep-15, Volume: 110, Issue:6 Topics: Adolescent; Adult; Aged; Double-Blind Method; Dyslipidemias; Female; Flushing; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Treatment Outcome; Young Adult	2012
Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. PloS one, 2012, Volume: 7, Issue:8 Topics: Blood Coagulation; Blood Platelets; Calcium; Dyslipidemias; Female; Gene Expression Regulation; Humans; Hypolipidemic Agents; Indoles; Male; Niacin; P-Selectin; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Prostaglandin D2; Receptors, Prostaglandin E, EP3 Subtype; Thrombosis	2012
Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice. Current medical research and opinion, 2013, Volume: 29, Issue:1 Topics: Age Factors; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Disease Management; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Sex Factors	2013
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. European heart journal, 2013, Volume: 34, Issue:17 Topics: Arterial Occlusive Diseases; Chemical and Drug Induced Liver Injury; Death, Sudden, Cardiac; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Myocardial Reperfusion; Niacin; Simvastatin; Stroke	2013
Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. European journal of clinical investigation, 2013, Volume: 43, Issue:7 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoproteins B; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Pilot Projects; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors	2013
Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction. Heart and vessels, 2014, Volume: 29, Issue:3 Topics: Adult; Biomarkers; Brachial Artery; Cholesterol, HDL; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Myocardial Infarction; Niacin; Slovenia; Time Factors; Treatment Outcome	2014
Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype. Metabolism: clinical and experimental, 2014, Volume: 63, Issue:3 Topics: Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Genotype; Humans; Indoles; Lipoprotein(a); Lysophospholipids; Male; Middle Aged; Niacin; Polymorphism, Genetic; Triglycerides	2014
Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6 Topics: Adult; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Indoles; Lipid Metabolism; Niacin; Polycystic Ovary Syndrome; Postprandial Period; Risk Reduction Behavior; Treatment Outcome; Triglycerides; Young Adult	2014
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia. Cardiovascular therapeutics, 2014, Volume: 32, Issue:4 Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid	2014
Short-term effects of extended-release niacin with and without the addition of laropiprant on endothelial function in individuals with low HDL-C: a randomized, controlled crossover trial. Clinical therapeutics, 2014, Jun-01, Volume: 36, Issue:6 Topics: Aged; Cholesterol, HDL; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Dyslipidemias; Endothelium, Vascular; Female; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Vasodilation; Vasodilator Agents	2014
Effect of niacin on FGF23 concentration in chronic kidney disease. American journal of nephrology, 2014, Volume: 39, Issue:6 Topics: Aged; Calcium; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Parathyroid Hormone; Phosphorus; Receptors, Immunologic; Receptors, Prostaglandin; Renal Insufficiency, Chronic	2014
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia. Vascular health and risk management, 2014, Volume: 10 Topics: Adult; Aged; Apolipoproteins B; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Linear Models; Middle Aged; Niacin; Risk Factors; Simvastatin; Time Factors; Treatment Outcome	2014
Effects of extended-release niacin with laropiprant in high-risk patients. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Aged; Atherosclerosis; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Male; Middle Aged; Musculoskeletal Diseases; Niacin; Risk Factors; Treatment Failure	2014
Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis, 2015, Volume: 238, Issue:2 Topics: Adult; Aged; Antioxidants; Biomarkers; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; High-Density Lipoproteins, Pre-beta; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Metabolomics; Middle Aged; Niacin; Oxidants; Particle Size; Prospective Studies; Simvastatin; Spain; Time Factors; Treatment Outcome; Up-Regulation	2015
Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control. Vascular health and risk management, 2015, Volume: 11 Topics: Aged; Biomarkers; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Interactions; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Indoles; Lipids; Male; Middle Aged; Niacin; Time Factors; Treatment Outcome	2015
Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia. Disease markers, 2015, Volume: 2015 Topics: Adiponectin; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; China; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Indoles; Insulin; Insulin Resistance; Male; Middle Aged; Niacin; Vitamin B Complex	2015
Detrimental effects of niacin/laropiprant on microvascular reactivity and red cell deformability in patients with elevated lipoprotein(a) levels. Journal of thrombosis and thrombolysis, 2016, Volume: 41, Issue:3 Topics: Aged; Erythrocyte Deformability; Female; Humans; Indoles; Lipoprotein(a); Male; Microcirculation; Middle Aged; Niacin	2016
Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients. Journal of the American Heart Association, 2015, Sep-15, Volume: 4, Issue:9 Topics: Adult; Aged; Apolipoprotein B-100; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Dyslipidemias; England; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation Mediators; Lipoproteins, LDL; Male; Middle Aged; Niacin; Time Factors; Treatment Outcome; Young Adult	2015
Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport. Arteriosclerosis, thrombosis, and vascular biology, 2016, Volume: 36, Issue:2 Topics: Aged; Animals; Anticholesteremic Agents; Apolipoprotein B-100; Biological Transport; Cell Line, Tumor; CHO Cells; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cricetulus; Drug Combinations; Dyslipidemias; Feces; Female; Humans; Indoles; Liver; Macrophages; Male; Mice, Transgenic; Middle Aged; Niacin; Postprandial Period; Time Factors; Transfection; Treatment Outcome	2016
Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes. Lipids in health and disease, 2016, Jul-12, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein B-100; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Indoles; Insulin; Male; Middle Aged; Niacin; Triglycerides	2016
Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. Circulation. Cardiovascular quality and outcomes, 2016, Volume: 9, Issue:4 Topics: Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; China; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Combinations; Drug Costs; Drug Therapy, Combination; Dyslipidemias; Female; Hospital Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Indoles; Lipids; Male; Middle Aged; Niacin; Quality of Life; Quality-Adjusted Life Years; Risk Factors; Scandinavian and Nordic Countries; Time Factors; Treatment Outcome; United Kingdom	2016
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. Circulation. Genomic and precision medicine, 2018, Volume: 11, Issue:2 Topics: Aged; Coronary Disease; Female; Humans; Hypolipidemic Agents; Indoles; Lipoprotein(a); Male; Middle Aged; Niacin; Protein Isoforms; Risk Factors; Simvastatin	2018
Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. Clinical therapeutics, 2019, Volume: 41, Issue:9 Topics: Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Hemorrhage; Humans; Hypolipidemic Agents; Incidence; Indoles; Infections; Male; Niacin	2019

Other Studies

23 other study(ies) available for niacin and mk-0524

Article	Year
Molecule of the Month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides. Current topics in medicinal chemistry, 2008, Volume: 8, Issue:14 Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Humans; Hypercholesterolemia; Indoles; Niacin; Triglycerides	2008
Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clinical therapeutics, 2009, Volume: 31, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Humans; Hypertension; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Randomized Controlled Trials as Topic; Young Adult	2009
Nicotinic acid + larodiorant. Laropiprant adds its own adverse effects. Prescrire international, 2010, Volume: 19, Issue:105 Topics: Drug Combinations; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Pregnancy; Randomized Controlled Trials as Topic	2010
Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany. The European journal of health economics : HEPAC : health economics in prevention and care, 2012, Volume: 13, Issue:3 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Dyslipidemias; Female; Germany; Health Care Costs; Humans; Hypolipidemic Agents; Indoles; Life Expectancy; Male; Middle Aged; Models, Economic; Niacin; Risk Assessment; Secondary Prevention; Simvastatin	2012
Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2011, Volume: 57, Issue:6 Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Hypophosphatemia; Indoles; Kidney Failure, Chronic; Lipids; Niacin; Treatment Outcome	2011
Paradoxical decrease in serum high-density lipoprotein cholesterol with Tredaptive® (m/r nicotinic acid 1 g and laropiprant 20 mg). Annals of clinical biochemistry, 2011, Volume: 48, Issue:Pt 6 Topics: Adult; Cholesterol, HDL; Drug Combinations; Drug Substitution; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Indoles; Male; Niacin; Treatment Outcome; Triglycerides	2011
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3 Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Indoles; Lipids; Lipoprotein(a); Male; Niacin; Randomized Controlled Trials as Topic	2012
Bullous drug eruption secondary to nicotinic acid/laropiprant. Annals of the Academy of Medicine, Singapore, 2012, Volume: 41, Issue:3 Topics: Drug Combinations; Drug Eruptions; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Skin Diseases, Vesiculobullous	2012
High patient compliance with nicacin/laropiprant in large clinical trial: interim safety and tolerability results from HPS-2 THRIVE study released at 2012 ESC congress: drug trends in cardiology. Cardiovascular journal of Africa, 2012, Volume: 23, Issue:8 Topics: Chemical Safety; China; Cholesterol, HDL; Coronary Artery Disease; Europe; Follow-Up Studies; Humans; Indoles; Lipid Metabolism; Muscular Diseases; Niacin; Patient Compliance; Randomized Controlled Trials as Topic	2012
Extended-release niacin/laropiprant for lipid management: observational study in clinical practice. International journal of clinical practice, 2013, Volume: 67, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Prospective Studies; Young Adult	2013
The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin. European heart journal, 2013, Volume: 34, Issue:17 Topics: Arterial Occlusive Diseases; Chemical and Drug Induced Liver Injury; Female; Humans; Hypolipidemic Agents; Indoles; Male; Muscular Diseases; Niacin	2013
Dyslipidaemia: Failure to THRIVE: the end for niacin? Nature reviews. Cardiology, 2013, Volume: 10, Issue:5 Topics: Biomarkers; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipids; Niacin; Treatment Outcome	2013
When clinical trials fail to address treatment gaps: the failure of niacin-laropiprant to reduce cardiovascular events. Current atherosclerosis reports, 2013, Volume: 15, Issue:6 Topics: Arterial Occlusive Diseases; Chemical and Drug Induced Liver Injury; Female; Humans; Hypolipidemic Agents; Indoles; Male; Muscular Diseases; Niacin	2013
HPS2-THRIVE results: bad for niacin/laropiprant, good for ezetimibe? Atherosclerosis, 2013, Volume: 229, Issue:2 Topics: Adaptor Protein Complex 3; Adaptor Protein Complex beta Subunits; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans; Hypolipidemic Agents; Indoles; Niacin; Simvastatin	2013
A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients. Journal of clinical pharmacy and therapeutics, 2013, Volume: 38, Issue:6 Topics: Adult; Aged; Anti-Inflammatory Agents; Biopsy; Body Weight; Drug Combinations; Drug Eruptions; Exanthema; Female; Histamine Antagonists; Hong Kong; Humans; Indoles; Male; Middle Aged; Niacin; Pruritus; Skin; Vitamins	2013
Niacin and statin intolerable for some people. European heart journal, 2013, Volume: 34, Issue:33 Topics: Arterial Occlusive Diseases; Clinical Trials as Topic; Delayed-Action Preparations; Drug Eruptions; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Niacin; Prostaglandin D2; Vasodilator Agents	2013
Nicotinic acid plus laropiprant suspended for dyslipidaemia. The lancet. Diabetes & endocrinology, 2013, Volume: 1 Suppl 1 Topics: Cholesterol, HDL; Drug Combinations; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Niacin; Product Surveillance, Postmarketing	2013
Niacin and HDL cholesterol--time to face facts. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Male; Niacin	2014
Niacin fails to reduce vascular events in large randomised trial. BMJ (Clinical research ed.), 2014, Jul-22, Volume: 349 Topics: Blood Glucose; Cholesterol, HDL; Delayed-Action Preparations; Diabetes Mellitus; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Infections; Lipoproteins, LDL; Niacin; Randomized Controlled Trials as Topic; Receptors, Immunologic; Receptors, Prostaglandin	2014
Placing HPS2-THRIVE in context using Bayesian analysis. International journal of cardiology, 2015, Sep-15, Volume: 195 Topics: Bayes Theorem; Cardiovascular Diseases; Delayed-Action Preparations; Dyslipidemias; Flushing; Humans; Indoles; Lipid Regulating Agents; Niacin; Prostaglandin D2; Risk Assessment	2015
Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia. Pharmacogenomics, 2015, Volume: 16, Issue:12 Topics: Asian People; Body Mass Index; Drug Therapy, Combination; Dyslipidemias; Female; Flushing; Hong Kong; Humans; Indoles; Male; Middle Aged; Niacin; Pharmacogenetics; Polymorphism, Genetic; Skin	2015
Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes. Scientific reports, 2016, Jan-18, Volume: 6 Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Fluorescent Dyes; Humans; Indoles; Lipid Metabolism; Lipids; Magnetic Resonance Spectroscopy; Male; Microscopy, Atomic Force; Middle Aged; Niacin; Simvastatin; Surface Properties; Triglycerides	2016
Investigating modifications to participant information materials to improve recruitment into a large randomized trial. Trials, 2019, Dec-05, Volume: 20, Issue:1 Topics: Aged; Aged, 80 and over; Focus Groups; Humans; Indoles; Middle Aged; Niacin; Patient Participation; Patient Selection; Randomized Controlled Trials as Topic; Vascular Diseases	2019

chemdatabank.com